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Aim: Irritable bowel syndrome (IBS), a functional disorder of the bowel, has been thought to result from immune activation. The aim
of this study was to evaluate macrophage migration inhibitory factor (MMIF) and monocyte chemotactic protein-1 (MCP-1) levels in
IBS patients.
Materials and methods: We enrolled 30 IBS patients and 30 healthy controls. The MMIF and MCP-1 levels of all patients and controls
were detected using commercial enzyme-linked immunosorbent assay kits.
Results: Serum MMIF and MCP-1 levels were markedly higher in IBS patients than in controls. White blood cell, neutrophil, lymphocyte,
monocyte, eosinophil, and basophil counts did not differ significantly between groups.
Conclusion: These results show that alterations in MMIF and MCP-1 affect the proinflammatory process. They also suggest that MMIF
and MCP-1 may play a substantial role in IBS.
Key words: Irritable bowel syndrome, macrophage migration inhibitory factor, monocyte chemotactic protein, inflammation

1. Introduction
Irritable bowel syndrome (IBS) is one of the most prevalent
gastrointestinal sicknesses and causes considerable
morbidity amongst its sufferers (1). It is a functional bowel
disease that usually occurs, or is exacerbated, during
periods of emotional stress, and it progresses mainly
with stomach aches or changes in defecation habits, like
diarrhea or constipation. It is not linked to any known
organic cause. Despite many studies, the pathophysiology
of IBS is still uncertain. Hereditary and environmental
factors affect the occurrence of IBS (2). Initially infections
were blamed, but solid evidence could not be put forward
to support this. Studies on visceral hypersensitivity and
abnormal gastrointestinal motility as the primary sources
of symptoms mainly focused on infections, inflammations,
changes in microflora, excessive bacterial increase,
genetics, and dysregulation of serotonin and the central
nervous system. Both histological specimens obtained
from endoscopy and serological cytokine studies have
demonstrated low-grade inflammation in IBS (3).
Macrophage migration inhibitory factor (MMIF),
which was first ascertained as the product of T cells, is
* Correspondence: ftulubas@yahoo.com

described as a factor that inhibits desultory immigration
of macrophages. Previous studies showed that MMIF
could be produced as an immunoregulatory protein by
several cells other than T cells (4). The immunological
and hormonal effects of MMIF have been defined (5).
Some findings refer to the fact that MMIF also promotes
leukocyte accumulation during pathological inflammatory
responses (6). As a proinflammatory cytokine, MMIF
induces the secretion of some cytokines such as tumor
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), thus
taking a role in the pathogenesis of some inflammatory
diseases and cancers (7).
Monocyte chemotactic protein-1 (MCP-1) is a member
of the CC chemokine subfamily and is coded by the CCL2
gene (8). It is produced by monocytes, lymphocytes,
vascular smooth muscle cells, tubular epithelial cells, and
endothelial cells as a response to inflammatory stimuli
including TNF-α, interferon-α, lipopolysaccharide, IL1, and oxide low-density lipoprotein. It also acts as an
intracellular messenger that controls leukocyte activation
and migration linked to inflammatory reaction and
immunity (9). It has been determined that in vitro MCP-
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1 could induce monocyte chemotaxis, which could carry
a subgroup of T cells and IL-2-activated natural killer
cells to the locality. Due to its target cell specificity, MCP1 has a pathological role in several diseases described by
mononuclear cell infiltration, including atherosclerosis,
neoplasm, inflammatory diseases, and HIV (9).
It should be clear that both MMIF and MCP-1 can play
a critical role in the pathogenesis of inflammatory diseases.
We aimed to research whether there is a relationship
between serum levels of these proinflammatory agents
and the low-grade inflammation that has a role in the
pathogenesis of IBS.
2. Materials and methods
2.1. Patients and controls
The study included 30 patients (20 females, 10 males;
mean age: 45 ± 10 years) who had applied to Namık
Kemal University Faculty of Medicine, Department of
Gastroenterology, and were diagnosed with IBS according
to the Rome III criteria and who had no alarm symptoms,
had no chronic disease history, and had macroscopically
normal colonoscopic findings (10). There were 30 control
patients (17 females, 13 males; mean age: 49 ± 11 years)
who had no history of chronic disease or drug use, who
were undergoing colonoscopy for reasons not related to
IBS, and who had macroscopically normal colonic mucosa.
Exclusion criteria were alcohol and substance abuse or
dependence, presence of severe organic disorders, use of
any antioxidants, presence of gastroenterological disorder,
presence of infectious or viral disease, and excessive
obesity. The vital signs of all patients were recorded
just before the colonoscopy by the anesthesiologist. All
equipment needed for cardiopulmonary resuscitation was
ready for use in the endoscopy unit. All drugs used during
colonoscopy were administered by an anesthesiologist.
2.2. Biochemical analysis
Blood samples were obtained to determine MMIF and
MCP-1 levels after overnight fasting. The serum samples
obtained after centrifugation were then immediately
frozen at –80 °C until further analysis of MMIF and MCP1. The serum levels of MMIF (Quantikine Human MIF
ELISA; R&D Systems) and MCP-1 (Quantikine Human
CCL2/MCP-1 ELISA; R&D Systems) were specified
with commercial enzyme-linked immunosorbent assay
(ELISA) kits. MMIF and MCP-1 were measured in a
sandwich-assay format using 2 specific high-affinity
antibodies, streptavidin peroxidase conjugate and a
chromogenic substrate. The minimum detectable level
of MMIF and MCP-1 is 0.016 ng/mL and 1.7 pg/mL
respectively. Complete blood cell count was determined
by using a Roche Sysmex XT-2000i autoanalyzer and the
same brand of commercial kits.
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2.3. Statistical analysis
PASW 18 Statistics for Windows was used to record and
analyze data on a computer. All results were expressed as
mean ± SD. The Kolmogorov–Smirnov test was used to test
the normality assumption for each variable. The group means
were compared by using the independent sample t-test. The
Pearson correlation coefficient was used to determine the
relation between continuous variables. The results were
considered to be statistically significant at P < 0.05.
2.4. Ethical considerations
The study was carried out in accordance with the
Declaration of Helsinki II with approval of the ethics
committee of the Namık Kemal University Faculty of
Medicine. All participants were informed about the study
protocol and written consent was obtained from each of
them.
3. Results
Demographic data, white blood cell count, and subgroup
cell counts are given in the Table. White blood cell,
neutrophil, lymphocyte, monocyte, eosinophil, and
basophil counts did not differ significantly between groups
(Table). Serum MMIF levels were significantly lower (P =
0.013) in the IBS group (37.43 ± 8.42 ng/mL) compared
with the control group (32.66 ± 5.79 ng/mL) (Figure 1).
MCP-1 levels were significantly lower (P = 0.00) in the
IBS group (337.93 ± 58.77 pg/mL) compared with the
control group (287.15 ± 41.76 pg/mL) (Figure 2). There
was no correlation between MMIF and MCP-1 levels in
IBS patients (r = 0.019, P = 0.920) (not shown).
Table. Demographic parameters, white blood cell count, and
subgroup counts for the groups (mean ± SD).
Control
(mean ± SD)

IBS
(mean ± SD)

Sex (M / F)

13 / 17

10 / 20

Age (years)

49 ± 11

45 ± 10

BMI (kg/m2)

27.7 ± 8.3

30 ± 18

WBC (109/L)

7.6 ± 2.4

6.8 ± 1.6

NE (10 /L)

4.4 ± 1.8

3.7 ± 1.3

LY (10 /L)

2.4 ± 0.8

2.3 ± 0.5

MO (109/L)

0.65 ± 0.24

0.59 ± 0.18

EO (109/L)

0.17 ± 0.13

0.12±0.08

BA (10 /L)

0.15 ± 0.07

0.15 ± 0.05

9

9

9

BMI: Body mass index, WBC: white blood cell count, NE:
neutrophil count, LY: lymphocyte count, MO: monocyte count,
EO: eosinophil count, BA: basophil count.
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Figure 1. MMIF serum levels of the patients with IBS and
controls (*: P = 0.013).

Figure 2. MCP-1 serum levels of the patients with IBS and
controls (*: P = 0.000).

4. Discussion
In our study, we did not observe any significant change in the
counts of white blood cells and subgroups. Nonsignificant
decreases in counts of white blood cell and subgroups
show that cellular immunity has a role in IBS development.
Schoepfer et al. did not find significant changes in
blood leukocyte levels of patients with IBS compared to
healthy volunteers (11). In other research, Arévalo et al.
suggested that there was no significant difference in mast
cells, enterochromaffin cells, or eosinophils in the colonic
mucosa of patients with IBS (12). Lee et al. supposed that
there was no significant difference in lamina propria T
lymphocyte counts between IBS patients and controls
(13). Our findings match the results of these studies, which
indicates that counts of white blood cells and subgroups
cannot be a marker of IBS.
In our study, we found that serum MMIF levels
of patients with IBS increased significantly compared
with controls, which supports the development of
inflammation in IBS. MMIF, which is a proinflammatory
cytokine, is considered to have strong antiglucocorticoid
effects and is linked to a variety of inflammatory diseases.
MMIF inhibits MKP1 induction and thus inhibits the
antiinflammatory effects of glucocorticoids, which
induce MMIF (14). MMIF was shown to specifically
counteract the glucocorticoid-induced suppression of
inflammatory cytokine (TNF and interleukins) secretion
in activated macrophages (15). Ishiguro et al. found that
MMIF expression was enhanced in colonic mononuclear
cells of patients with glucocorticoid-resistant ulcerative
colitis and they stated that the antiinflammatory
response to glucocorticoids in these cells was restored
by anti-MMIF antibody (16). In their experimental
study, Ogawa et al. stated that tumorigenesis due to an
increase in angiogenesis resulting from the treatment of

murine colon adenocarcinoma cells with anti-MMIF
antibodies was suppressed, which suggests that MMIF
could be associated with the development of tumor cell
development (17). Huang et al. observed a significant
upregulation in MMIF and MMIF mRNA and suggested
that MMIF was mainly produced by macrophages, not
neutrophils, in murine acute gastric ulcers. This was linked
to the significant inhibition of macrophage and neutrophil
accumulation and activation, which reduced ulcer sizes
and attenuated ulceration (18). It has been suggested
that MMIF protein was significantly increased in Crohn’s
disease and ulcerative colitis (UC). It was also suggested
that MMIF significantly increased the production of IL-8
in UC patients compared with non-UC patients (19).
Immune deficiency and inflammation are considered to
be significant factors in the pathogenesis of IBS. Cytokines
can affect bowel motility, permeability, and secretion, since
they can affect epithelial cells, smooth muscles, and the
enteric nervous system. Thus, it is suggested that cytokines
could lead to IBS symptoms (20). Long et al. reported
that immune cells were increased and mucosal immune
systems were activated in the biopsy samples of patients
with IBS (21). Studies on patients with IBS reported that
proinflammatory cytokine levels were increased while
antiinflammatory cytokine levels were decreased. In their
study, Hua et al. reported that levels of IL-10, which is an
antiinflammatory cytokine, were decreased in patients
with IBS, whereas levels of proinflammatory cytokines
such as IL-6 and TNF-α were increased. In the same
study, it was claimed that the increase in the expression
of IL-6, IL-8, and TNF-α, together with a decrease in the
expression of IL-10 and IL-12, could be a risk factor in
the development of IBS symptoms (22). Olivio-Diaz et
al. stated that the inducement of IL-8 production and a
decrease or deficiency in IL-10 production could trigger
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the inflammatory process in patients with IBS (23).
Dinan et al. stated a relation between IL-6 levels and IBS
pathophysiology (24). These studies indicate a possible
relation between the pathogenesis of IBS and an increase
in proinflammatory cytokines caused by MMIF and a
decrease in antiinflammatory cytokines.
Our findings suggest that MCP-1 levels increased
significantly in patients with IBS, which matches the
findings of previous studies. Studies have also found that,
as well as proinflammatory cytokines, chemokine levels,
and especially levels of MCP-1, IL-8, IL-1, and TNF, were
increased in inflammatory bowel disease and showed a
possible relation between MMIF and MCP-1 (25). The
presence of MCP-1 is considered to be responsible for the
massive invasion of blood monocytes and granulocytes
to the inflamed tissue. Herrero et al. showed that MCP1 levels were significantly reduced in rats with MMIF
deficiency (26). Exogenous MMIF is considered to
promote monocyte recruitment in vivo, partly through
inducing endothelial release of CCL2/MCP-1. Our
findings suggest that endogenous MMIF promotes
TNF-induced p38 activation, which supports increased
expression of adhesion molecules and chemokines (27).
MMIF deficiency also has some inhibitory effects on
CCL2-induced leukocyte adhesion and migration in
vivo, migration in vitro, and cellular responses such as
mitogen-activated protein kinase activation and actin

polymerization. Experiments in CCL2-/- mice showed that
MMIF-stimulated leukocyte adhesion and out-migration
were both significantly decreased compared with MMIFtreated wild-type mice. It was also found that exposure to
MMIF significantly increased CCL2 release. Specificity of
MMIF for monocyte clustering resulted from a pathway
involving the monocyte-attracting chemokine CCL2 and
its monocyte-expressed receptor, CCR2. Blockade of
CCL2 or CCR2 significantly reduces leukocyte adhesion
and transmigration. Release of CCL2 from endothelial
cells is induced by MMIF, and thus CCL2 promotes the
adhesion and recruitment of monocytes. Macrophagemediated inflammatory responses were also promoted by
MMIF, through inducing the recruitment of monocytes
into affected areas. MMIF could also have a role in the
initiation and perpetuation of inflammation-associated
diseases through attracting and activating monocytes or
macrophages (28).
In conclusion, high levels of such proinflammatory
mediators as MMIF and MCP-1 in patients with IBS
were observed in the present study, which supports the
claim that inflammation could be an effective factor
in the pathogenesis of IBS and clarifies the increased
production of proinflammatory cytokines. We consider
that development of mechanisms or molecules inhibiting
the activation of MMIF and MCP-1 could promote the
treatment of IBS.
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